Medscape |
Autoimmunity a Player in Autism
Medscape A new study suggests that about 1 in 10 mothers of children with autism have antibodies that react with proteins in the brain of their children, and these antibrain antibodies correlate with maternal autoimmunity. “This study strongly suggests that … |
Research and Markets: Antibodies in Oncology Drug Pipeline Update 2013 …The Herald | HeraldOnline.comThe commercial and therapeutic success of antibodies like Rituxan, Avastin, and Erbitux will force the industry to look into the next generation of t…
RESEARCH AND MARKETS: Antibodies in Oncology Drug Pipeline Update …4-traders (press release)The commercial and therapeutic success of antibodies like Rituxan, Avastin, and Erbitux will force the industry to look into the next generation of therapeuti…
|
Pixantrone-based regimen associated with lower cardiotoxicity in patients with …
Healio … and colleagues conducted the investigation to compare the safety and efficacy of R-CHOP chemotherapy — cyclophosphamide, doxorubicin, vincristine, prednisone and rituximab (Rituxan; Genentech, Idec Pharmaceuticals) — with R-CPOP, substituting … |
Laboratory EquipmentAntibodies Quickly Detect Foodborne VirusLaboratory EquipmentViroStat has developed two new sets of MONOTOPE monoclonal antibodies to the major capsid protein of the GI and GII Noroviruses. These antibodies function in ELISA and lat…
Engineered antibodies market to be worth $5.7 billion by 2023: reportThe Pharma LetterThe market for engineered antibodies is forecast to reach a value of $5.7 billion by 2023, according to a new report for Root Analysis, titled Fc Protein GLycoenginee…
Astellas and Merck CollaborateYahoo! News… when it launched Astagraf XL in the U.S. Astagraf XL was approved in the U.S. in Jul 2013 for the prophylaxis of organ rejection in patients receiving a kidney transplant used with mycophenolate mofetil (MMF…
Astellas and Merck Collaborate – Analyst BlogNASDAQ… when it launched Astagraf XL in the U.S. Astagraf XL was approved in the U.S. in Jul 2013 for the prophylaxis of organ rejection in patients receiving a kidney transplant used with mycophenolate mo…
Astellas and Merck CollaborateZacks.com… when it launched Astagraf XL in the U.S. Astagraf XL was approved in the U.S. in Jul 2013 for the prophylaxis of organ rejection in patients receiving a kidney transplant used with mycophenolate mofetil (MMF) …
|
Engineered Antibodies Market to be Worth USD 5.7 Billion by 2023: Report by …
PharmiWeb.com (press release) Roots Analysis has announced the addition of the ‚ÄúFc Protein and Glycoengineered Antibodies Market 2013-2023‚Äù report to their offering. The report provides an extensive study of this emerging field including detailed sales forecast (till 2023) of … |